VBI Vaccines Announces Results of Annual General Meeting

VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 23, 2023 (the "Meeting").

The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 5,560,730 Common Shares, representing 64.60% of VBI's issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2023.

The voting results with respect to each of the following eight director nominees, as described in the Company's proxy statement dated May 1, 2023 (the "Proxy Statement"), all of whom previously served as directors of the Company, were as follows:

Nominee		Votes For		%		Votes Withheld		%
Steven Gillis		2,149,267		84.82%		384,590		15.18%
Damian Braga		2,277,929		89.90%		255,931		10.10%
Joanne Cordeiro		2,327,969		91.87%		205,888		8.13%
Michel De Wilde		2,276,500		89.84%		257,357		10.16%
Vaughn Himes		2,284,875